We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcutis Biotherapeutics, Inc. is one of 973 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 20.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARQT has returned about 13.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Foghorn Therapeutics Inc. (FHTX - Free Report) . The stock is up 17.2% year-to-date.
In Foghorn Therapeutics Inc.'s case, the consensus EPS estimate for the current year increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 486 individual stocks and currently sits at #159 in the Zacks Industry Rank. On average, this group has gained an average of 3.2% so far this year, meaning that ARQT is performing better in terms of year-to-date returns. Foghorn Therapeutics Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Arcutis Biotherapeutics, Inc. and Foghorn Therapeutics Inc.. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcutis Biotherapeutics, Inc. is one of 973 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 20.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARQT has returned about 13.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Foghorn Therapeutics Inc. (FHTX - Free Report) . The stock is up 17.2% year-to-date.
In Foghorn Therapeutics Inc.'s case, the consensus EPS estimate for the current year increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 486 individual stocks and currently sits at #159 in the Zacks Industry Rank. On average, this group has gained an average of 3.2% so far this year, meaning that ARQT is performing better in terms of year-to-date returns. Foghorn Therapeutics Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Arcutis Biotherapeutics, Inc. and Foghorn Therapeutics Inc.. These stocks will be looking to continue their solid performance.